Biocure Enters into Exclusive Joint R&D Agreement with Pharos Vaccine Inc. for Overseas Market of CAR T-Cell Products
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (formerly Gravis Energy Corp.) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has entered into an agreement with Pharos Vaccine Inc. for the development of overseas market of CAR T-cell products on exclusive basis. The two Companies will work together in developing anti-CD19 CAR T-cell therapy products, conduct...
2019-05-16 8:40 AM EDT
Biocure Announces the Appointment of a New Director
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that effective of today's date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc. After completing a PhD in Biochemistry at Texas A&M university and an MBA at Rice University, Danny Joh moved to the San Francisco area to build a career in the biopharma industry. For twenty years, he has expanded his...
2019-03-14 9:00 AM EDT
BiocurePharm, Korea ("BPK") Announces Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2019) - Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 96,404 shares at $11.45 CAD per share for gross proceeds of $1,103,749. After the issuance of new BPK shares,...
2019-02-28 4:30 PM EST
Biocure Technology Corp Announces a MOU with the Government of Uzbekistan and Gold-Dream LLC to Build a Manufacturing Plant to Produce Biosimilars
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a Memorandum of Understanding with the Agency of Development of the Pharmaceutical Industry under the Ministry of Health, The Republic of Uzbekistan (herein after called "MHU") and Gold-Dream LLC (herein after called "GDL") on Feb 15th, 2019...
2019-02-19 9:00 AM EST
Biocure Technology Inc. Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has arranged a non-brokered private placement of 6,976,745 million units at 43 cents per unit for gross proceeds of $3 Million or more, depending on investor interest. Each Unit will entitle the holder to receive one common share of the Company (each a "Common Share") and one Full Warrant ("Warrants") exercisable for...
2019-02-14 9:00 AM EST
Biocure Shares DTC Eligible
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that its OTCQB-listed common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies....
2019-02-07 9:00 AM EST
Biocure Signs a Collaboration Agreement with Y Biologics
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a collaboration agreement with Y Biologics ("YB"), a private R&D company in Korea who is specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease. The purpose of this agreement is to research the effectiveness...
2019-01-14 9:00 AM EST
Biocure Operations Report
2018 In Brief Positive Pre-Clinical Trial Results on Leukemia CAR-T Cell Therapy Development Successful Toxicity Tests on Multiple Sclerosis Treatment Acquired 6,060 Square Meters Land for Biosimilar Manufacturing Facilities Completed OTC Listing Signed Strategic Agreements with Research Partners Expanded the Board of Directors Established
2018-11-19 9:15 AM EST
Biocure Announces: Breakthrough Pre-Clinical Trial Results for CAR-T Cells Treatment of Acute Leukemia
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2018) - Biocure Technology Inc. (CSE: CURE) (O
2018-10-16 10:22 AM EDT